BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol 2019;6:e000307. [PMID: 31523440 DOI: 10.1136/bmjgast-2019-000307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
2 Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, Starostin KM. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol 2020;7:e000341. [PMID: 32095253 DOI: 10.1136/bmjgast-2019-000341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
3 Dajani AI, Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect 2021;37:249-64. [DOI: 10.1007/s40267-021-00838-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol 2020;7:e000368. [PMID: 32337059 DOI: 10.1136/bmjgast-2019-000368] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
5 Vulf M, Shunkina D, Komar A, Bograya M, Zatolokin P, Kirienkova E, Gazatova N, Kozlov I, Litvinova L. Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis. Front Cell Dev Biol 2021;9:736677. [PMID: 34568346 DOI: 10.3389/fcell.2021.736677] [Reference Citation Analysis]
6 Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI, Palgova LK, Starostin K. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes 2021;8:369-82. [PMID: 33993460 DOI: 10.1007/s40801-021-00250-x] [Reference Citation Analysis]